Abstract |
The differences between topical corticosteroids are based mainly on their potency, safety and patient acceptability. The aim of this study was to evaluate a mild- to mid-potent topical corticosteroid, desonide 0.05%, on these three parameters in an Australian cohort of patients with facial seborrhoeic or atopic dermatitis. Eighty-one adult patients were randomized to receive desonide 0.05% lotion or its vehicle, applied twice daily for 3 weeks under double-blind conditions. In the active treatment group, 88% of patients had their skin condition cleared or almost cleared and only two patients experienced cutaneous adverse events ( rash and pruritus). The acceptability of the lotion was high; 95% of patients stated they would use this topical corticosteroid again. These data support the short-term use of desonide 0.05% lotion as a suitable agent for the short-term treatment of facial dermatitis.
|
Authors | Susanne Freeman, Anne Howard, Peter Foley, Robert Rosen, Glenda Wood, Jo-Ann See, Susan Gray |
Journal | The Australasian journal of dermatology
(Australas J Dermatol)
Vol. 43
Issue 3
Pg. 186-9
(Aug 2002)
ISSN: 0004-8380 [Print] Australia |
PMID | 12121395
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Inflammatory Agents
- Emulsions
- Glucocorticoids
- Desonide
|
Topics |
- Administration, Topical
- Adolescent
- Adult
- Anti-Inflammatory Agents
(adverse effects, therapeutic use)
- Australia
- Dermatitis, Atopic
(diagnosis, drug therapy)
- Dermatitis, Seborrheic
(diagnosis, drug therapy)
- Desonide
(adverse effects, therapeutic use)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Administration Schedule
- Emulsions
- Esthetics
- Facial Dermatoses
(diagnosis, drug therapy)
- Female
- Follow-Up Studies
- Glucocorticoids
- Humans
- Male
- Middle Aged
- Probability
- Reference Values
- Treatment Outcome
|